Պորտուգալիա - պորտուգալերեն - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

mylan, lda. - dasatinib - comprimido revestido por película - 100 mg - dasatinib 100 mg - dasatinib - genérico - duração do tratamento: longa duração

Պորտուգալիա - պորտուգալերեն - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

mylan, lda. - dasatinib - comprimido revestido por película - 100 mg - dasatinib 100 mg - dasatinib - genérico - duração do tratamento: longa duração

Պորտուգալիա - պորտուգալերեն - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

macleods pharma españa, slu - atomoxetina - cápsula - 18 mg - atomoxetina, cloridrato 20.52 mg - atomoxetine - genérico - duração do tratamento: curta ou média duração

Եվրոպական Միություն - պորտուգալերեն - EMA (European Medicines Agency)

eli lilly nederland b.v. - tadalafil - hipertensão, pulmonar - urologia - adultstreatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity (see section 5. a eficácia foi demonstrada na pah idiopática (ipah) e na pah relacionada à doença vascular do colágeno. paediatric populationtreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (pah) classified as who functional class ii and iii.

Եվրոպական Միություն - պորտուգալերեն - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - esclerose múltipla - imunossupressores seletivos - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Եվրոպական Միություն - պորտուգալերեն - EMA (European Medicines Agency)

sandoz gmbh - epoetina alfa - anemia; kidney failure, chronic - preparações antianêmicas - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis;, treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e. cardiovascular pré-existente anemia no início da quimioterapia).

Եվրոպական Միություն - պորտուգալերեն - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - leucemia linfoblástica com células precursoras - linfoma - agentes antineoplásicos - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Եվրոպական Միություն - պորտուգալերեն - EMA (European Medicines Agency)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimicóticos para uso sistêmico - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

Եվրոպական Միություն - պորտուգալերեն - EMA (European Medicines Agency)

mylan pharmaceuticals limited - darunavir - infecções por hiv - antivirais para uso sistêmico - darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv-1) infection (see section 4. darunavir mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4. 2):para o tratamento de hiv-1 de infecção em tratamento anti-retroviral (art)-experiente pacientes adultos, incluindo aqueles que foram altamente pré-tratados. para o tratamento de hiv-1 de infecção em pacientes pediátricos a partir da idade de 3 anos e pelo menos 15 kg de peso corporal. na decisão de iniciar o tratamento com darunavir co-administrado com baixa dose de ritonavir, cuidadosa consideração deve ser dada ao tratamento da história individual de cada paciente e os padrões de mutações associadas com diferentes agentes. genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4. 2, 4. 4 e 5. darunavir co-administrado com baixa dose de ritonavir é indicado em combinação com outros medicamentos anti-retrovirais para o tratamento de pacientes com vírus da imunodeficiência humana (hiv-1) infecção.  darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.  darunavir mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (art)-naïve (see section 4.  art-experienced with no darunavir resistance associated mutations (drv-rams) and who have plasma hiv-1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 10⁶/l. na decisão de iniciar o tratamento com darunavir em tal arte-pacientes experientes, genotypic testes devem orientar o uso de darunavir (consulte as secções 4. 2, 4. 3, 4. 4 e 5.

Եվրոպական Միություն - պորտուգալերեն - EMA (European Medicines Agency)

hexal ag - epoetina alfa - anemia; kidney failure, chronic; cancer - preparações antianêmicas - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. , o tratamento da anemia e redução de transfusão de requisitos em doentes adultos a receber quimioterapia para tumores sólidos, linfoma maligno ou mieloma múltiplo e em risco de transfusão de acordo com a avaliação do paciente estado geral (e. cardiovascular pré-existente anemia no início da quimioterapia).